Abstract

VORTIOXETINE HYDROBROMIDE: A CONCISE REVIEW

Avinash G. Tapkire* and Rushikesh S. Bachhav

ABSTRACT

Major depressive disorder (MDD) also referred to as depression, is one of the most severe and common psychiatric disorders across the world. The main therapeutic option in depression treatment is antidepressants. Regardless of large number of antidepressants, there are quiet limitations in their efficacy and tolerability. The objective of the review article is to precises the use of vortioxetine in clinical studies and assess the pharmacokinetics along with tolerability and efficacy. The arrival of vortioxetine as a model of antidepressant with multimodal activity and safe profile generate strong interest. Vortioxetine having two types of mechanisms. It have direct effect on several serotonin receptors and inhibition of serotonin transporter (SERT). Because of its unimodal mechanism of action, it does not belong to the selective serotonin re-uptake inhibitor (SSRI). It has good oral bioavailability because consumption of food does not affect the bioavailability, and taking vortioxetine with food has not been shown to increase its peak concentration. To attain maximum plasma concentration after dosing, and with multiple doses vortioxetine takes upto 3-16 hours. This review also included the drug profile which shows the all information regarding chemical and physical properties of vortioxetine.

Keywords: Major depressive disorder, vortioxetine, Anti-depressant, tolerability, efficiency.